Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY: CLS-AX in Neovascular AMD
NCT05891548Phase 2Completed
- Sponsor
- Clearside Biomedical
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Injectable Hydrogels, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of CLS-AX in neovascular age-related macular degeneration (NVAMD), sponsored by Clearside Biomedical. Started May 2023; status: completed.
02
Drugs
CLS-AX
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05891548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891548.